The Anglonordic Life Science Conference XII (www.anglonordiclifescience.com) gives you the opportunity to meet 300 decision makers representing leading and upcoming R&D companies from the Anglo-Nordic region and international pharmaceuticals and investment firms.
Members of the Oslo Cancer Cluster: PCI Biotech, Lytix Biopharma and Oncoimmunity will present.
Guest Country 2015 is Spain, who will participate with a delegation of R&D companies and investment firms incl. BIOIBERICA SA, Lipopharma Therapeutics, Era7 Bioinformatics, ArtinVet Innovative Therapies, Histocell, Ability Pharmaceuticals, InKemia IUCT group, Allinky Biopharma, Intelligent Pharma, DCN, BioSeed Capital (Group Biotech Development), OPERON, Caixa Capital Risc, ICEX, Asebio.
The organisers are happy to announce a record number of investors incl.: Abingworth, Belsize Asset Management, Caixa Capital Risc, DCN, Entrepreneurs Fund, Epidarex Capital, GHO Capital Partners, Hadean Ventures, Imperial Innovations, Industrifonden, InKemia IUCT group, InterPharm Investments, Investor Corporate, IPF Partners, JPIF, Karolinskadevelopment, Laguna Ventures, Midven Ltd, MS Ventures, MVM Life Science Partners, NeoMed, Norgine Ventures, Novo Seeds, Omega Funds, Oriel Securities, Oriel Securities/Stifel Europe, RBV Capital, S.R.One, Sarum Capital LLP, Scottish Equity Partners, SEED Capital, Seventure, Silicon Valley Bank, Sofinnova Partners, SPARK Impact, Syncona Partners, Syndicate Room, Tate & Lyle Ventures, Visium Asset Management, Wellington Partners and The Wellcome Trust.